Answers are grounded in this paper and cite their sources.
Cross-sectional study identifies barriers to access and suggests improvements for referral and specialist access.
Neurologists, hospital pharmacists (HP), and patients advocate for improved access to anti-CGRP monoclonal antibodies (mAbs) in migraine prophylaxis. To identify the barriers to access to anti-CGRP mAbs in Spain and to propose potential solutions. Cross-sectional study with online surveys aimed at neurologists, HPs, and patients. Descriptive statistics were used to analyse the data. Categorical variables were expressed in terms of frequency and percentage. A total of 55.1% of neurologists and 67.4% of HPs reported that at their hospitals, the criteria of the therapeutic positioning statement (TPS)were followed on a case-by-case basis to authorise the dispensing of anti-CGRP mAbs. However, more than 30% of neurologists and HPs reported that they had their own protocols. A total of 62.8% of neurologists and 23.3% of HPs disagreed with some TPS criteria and, according to 41.9% of pharmacists, not all neurologists at their hospital were able to prescribe anti-CGRP mAbs. Neurologists and HPs considered that the TPS criteria should be reviewed periodically. Some 32.9% of patients considered access to a migraine specialist to have been difficult. A total of 88.4% of neurologists and 81.4% of HPs thought that referral from primary care to a specialised consultation should be faster. The main barriers to accessing anti-CGRP mAbs are the difficulty of accessing a neurology specialist, and the strict TPS criteria and differences in their application between autonomous communities and hospitals. Neurology referral systems should be improved and TPS criteria reviewed. Neurólogos, farmacéuticos hospitalarios (FH) y pacientes abogan por mejorar el acceso a los anticuerpos monoclonales (ACM) anti-CGRP en la profilaxis de la migraña. identificar las barreras en el acceso a los ACM anti-CGRP en España. Estudio transversal con encuestas online dirigidas a neurólogos, FH y pacientes. Se emplearon estadísticos descriptivos para evaluar los datos. Las variables categóricas se expresaron en términos de frecuencia y porcentaje. Un 55,1% de los neurólogos y un 67,4% de FH manifestaron que en su hospital se siguen los criterios del informe de posicionamiento terapéutico (IPT) caso a caso para autorizar la dispensación de ACM anti-CGRP. Sin embargo, más de 30% de neurólogos y FH refirieron que tienen protocolos propios. El 62,8% de los neurólogos y el 23,3% de FH mostraron su desacuerdo con algunos criterios del IPT y según un 41,9% de FH no todos los neurólogos de su hospital pueden prescribir ACM anti-CGRP. Neurólogos y FH estiman que los criterios del IPT debería revisarse periódicamente. Un 32,9% de los pacientes consideraron difícil el acceso a un especialista en migraña. El 88,4% de neurólogos y el 81,4% de los FH opinaron que debe acelerarse la derivación desde atención primaria a una consulta especializada. Las principales barreras para acceder a los ACM anti-CGRP son la dificultad de acceso a un especialista en neurología, los estrictos criterios del IPT y su diferente aplicación entre distintas CC.AA. y hospitales. Deben mejorarse los sistemas de derivación a neurología y revisarse los criterios del IPT.
No takes yet. Share an insight, caveat, or question.
Irimia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: